Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 2008 (First Quarter of Fiscal 2008)
Business Overview: The Company operates through two primary segments: CooperVision (CVI), which develops and markets contact lenses, and CooperSurgical (CSI), which manufactures medical devices and surgical instruments for gynecologists and obstetricians.
Key Financial Metrics
| Metric (in thousands) | Q1 2008 | Q1 2007 |
|---|---|---|
| Net Sales | $245,033 | $219,420 |
| Gross Profit | $142,882 | $129,912 |
| Gross Margin | 58.3% | 59.2% |
| Operating Income | $19,951 | $15,762 |
| Net Income | $6,877 | $5,348 |
| Diluted EPS | $0.15 | $0.12 |
| Cash and Equivalents | $2,586 | $3,226 (Oct 31, 2007) |
| Total Debt | $925,109 | $876,630 (Oct 31, 2007) |
| Operating Cash Flow | ($5,592) | $761 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12% year-over-year, driven by 12% growth in CooperVision and 10% growth in CooperSurgical. Constant currency growth was 7%.
- Profitability: Operating income rose 27% to $20.0 million. Net income increased 29% to $6.9 million.
- Margin Compression: Gross margin decreased slightly to 58% from 59%, attributed to manufacturing inefficiencies related to new silicone hydrogel products, integration costs, and unfavorable foreign currency impacts.
- Cash Flow: Operating cash flow turned negative ($5.6 million used) compared to a positive $0.8 million in the prior year, primarily due to inventory build-up for new product launches and payments related to the Ocular integration plan.
- Debt Levels: Total debt increased to approximately $925 million, reflecting increased long-term borrowings used for capital expenditures.
Outlook, Risks, and Management Commentary
- Product Launches: Management expects to launch Avaira, a two-week silicone hydrogel contact lens, in April 2008. The company is ramping up production capacity for silicone hydrogel products but faces challenges with manufacturing costs and late market entry.
- Integration Costs: The company is continuing the integration of Ocular Sciences Inc., with total restructuring costs estimated at $50 million. Approximately $12.1 million in production start-up and restructuring costs were incurred in the quarter.
- Capital Expenditures: Fiscal 2008 capital expenditures are expected to be between $160 million and $170 million, primarily for expanding silicone hydrogel manufacturing and consolidating distribution centers.
- Legal Proceedings:
- Securities Litigation: A consolidated class action lawsuit regarding alleged misstatements about the Biomedics product line and financial projections remains pending. The court denied the motion to dismiss claims related to false statements but dismissed claims regarding Sarbanes-Oxley certifications.
- Patent Litigation: A global settlement was reached with CIBA Vision in November 2007, resolving patent disputes regarding silicone hydrogel lenses. The settlement involves cross-licensing and future royalty payments by CooperVision.
- Tax Rate: The effective tax rate increased to 27.5% from 21.2% in the prior year, influenced by the geographic mix of income and expenses related to the Ocular integration plan.
Investor Verification Checklist
- Inventory Levels: Verify the recoverability of the increased inventory ($279 million) built in anticipation of new product launches (Biofinity and Avaira).
- Restructuring Progress: Monitor the realization of synergies from the Ocular Sciences integration and the total cost of the $50 million restructuring plan.
- Debt Servicing: Assess the impact of increased interest expense ($11.1 million) on future cash flows given the total debt load of $925 million.
- Legal Exposure: Track the status of the securities class action litigation and the financial impact of the CIBA Vision royalty agreement.
- Operating Cash Flow: Watch for the reversal of negative operating cash flow as inventory levels stabilize and new products gain market traction.